RELATED: Omicron shows need for global accord on pandemics, WHO chief saysIt's a global effort, but until recently the U.S.
was contributing very little. With uncoordinated and scattershot testing, the U.S. was sequencing fewer than 1% of positive specimens earlier this year.
Now, it is running those tests on 5% to 10% of samples."Genomic surveillance is strong," said Kelly Wroblewski, director of infectious diseases at the Association of Public Health Laboratories.The Biden administration will follow advice from Dr.